ETFs Seelos Therapeutics, Inc.

SEELQ

US81577F4063

Biotechnology & Medical Research

Delayed OTC Markets 17:25:32 01/06/2026 BST			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	+9,900.00%

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

ETFs positioned on Seelos Therapeutics, Inc.

Name		YTD change	Weight	AuM
VANGUARD ALL-EQUITY ETF PORTFOLIO - CAD		+16.18%	0%	12,086 M€

Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company